Pharmaceutical - GlaxoSmithKline

Filter

Current filters:

GlaxoSmithKline

Popular Filters

176 to 200 of 414 results

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

ViiV Healthcare’s Tivicay approved in Canada for HIV

04-11-2013

ViiV Healthcare, the HIV/AIDS joint venture set up by UK pharma giant GlaxoSmithKline with US behemoth…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

New data support GSK’s Cervarix two-dose schedule

New data support GSK’s Cervarix two-dose schedule

04-11-2013

UK pharma giant GlaxoSmithKline has revealed the results of a Phase III study of its HPV vaccine, Cervarix,…

CervarixGlaxoSmithKlineOncologyPharmaceuticalResearchVaccines

Theravance and GSK launch Breo Ellipta in USA

Theravance and GSK launch Breo Ellipta in USA

30-10-2013

GlaxoSmithKline and US partner Theravance today announced that Breo Ellipta for COPD is available to…

Breo ElliptaFinancialGlaxoSmithKlineMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and PulmonaryTheravance

GSK's third quarter results shows sales hit by China investigation

GSK's third quarter results shows sales hit by China investigation

24-10-2013

UK pharma major GlaxoSmithKline has released its third quarter results with sales hit hard by the investigation…

EuropeFinancialGlaxoSmithKlinePharmaceutical

Agreements for influenza vaccine approved in New Zealand

15-10-2013

New Zealand’s PHARMAC has reached agreements with subsidiaries of GlaxoSmithKline and Abbott Laboratories…

Abbott LaboratoriesFluarixGlaxoSmithKlineHealthcareInfluvacNew ZealandPharmaceuticalPricingVaccines

Analysts recommend GSK after Teva announces Advair generic delay

Analysts recommend GSK after Teva announces Advair generic delay

11-10-2013

The delay for the generic version of GlaxoSmithKline’s Advair coupled with the advances in the company’s…

AdvairdarapladibEuropeFinancialGlaxoSmithKlineNeurologicalPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

Global asthma treatment market to reach $21.6 billion by 2019

09-10-2013

The global asthma treatment market is estimated to reach a value of $21.6 billion by 2019, due not only…

GlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

Janssen gains rights to Ph II hepatitis C candidate from GSK

08-10-2013

Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

New data support GSK plan to file for approval of malaria vaccine in 2014

New data support GSK plan to file for approval of malaria vaccine in 2014

08-10-2013

Results from a large-scale Phase III trial, presented today at the Multilateral Initiative on Malaria…

GlaxoSmithKlinePharmaceuticalRegulationResearchRTS,STropical diseasesVaccines

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

GSK and Genmab file for Arzerra variation in Europe

04-10-2013

GlaxoSmithKline ) and partner Genmab have submitted a variation to the Marketing Authorization to the…

ArzerraBiotechnologyEuropeGenmabGlaxoSmithKlineOncologyPharmaceuticalRegulation

GSK stock will remain strong despite slowing emerging markets, say analysts

GSK stock will remain strong despite slowing emerging markets, say analysts

04-10-2013

Following concerns from Eli Lilly about the slowdown of emerging markets and devaluation of the Japanese…

EuropeFinancialGlaxoSmithKlineGSKPharmaceutical

GlaxoSmithKline agrees £700 million deal with Aspen

GlaxoSmithKline agrees £700 million deal with Aspen

30-09-2013

GlaxoSmithKline says it has now reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine,…

ArixtraAspen PharmacareCardio-vascularFraxiparineGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalRest of the World

UK’s NICE issues draft guidance on suite of ovarian cancer drugs

27-09-2013

Drugs watchdog the National Institute for Health and Care Excellence (NICE) is currently considering…

Europegemcitabine HclGlaxoSmithKlineJohnson & JohnsonLillyOncologyPharmaceuticalPricingRegulationtrabectedin

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

Prosensa stock goes into free fall as drisapersen fails in Ph III study

23-09-2013

UK pharma giant GlaxoSmithKline and Netherlands-based partner Prosensa announced on Friday that GSK's…

drisaperseneteplirsenGlaxoSmithKlinePharmaceuticalProsensaRare diseasesResearchSarepta Therapeutics

Positive CHMP recommendation for Relvar Ellipta

20-09-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) announced that the…

EuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance

US HHS replenishes nation's supply of anthrax antitoxin

20-09-2013

The USA’s supply of anthrax antitoxin will be maintained until 2018 under Project BioShield contracts…

Cangene CorpElusys TherapeuticsEmergent ProductsGlaxoSmithKlineHealthcareMarkets & MarketingNorth AmericaPharmaceuticalPharmAthene

US NIH trials flu vaccines from Sanofi and Novartis

US NIH trials flu vaccines from Sanofi and Novartis

19-09-2013

The US National Institutes of Health has begun testing an H7N9 avian influenza vaccine candidate in humans.

GlaxoSmithKlineHealthcareNorth AmericaNovartisPharmaceuticalSanofi PasteurVaccines

GlaxoSmithKline returns rights to vercirnon

19-09-2013

US drug developer ChemoCentryx (Nasdaq: CCXI) says that partner GlaxoSmithKline (LSE: GSK), the UK’s…

ChemoCentryxGastro-intestinalsGlaxoSmithKlineLicensingNorth AmericaPharmaceuticalvercirnon

GlaxoSmithKline, Community Care of North Carolina harness "small data" to improve patient care and reduce health care costs

18-09-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and Community Care of North Carolina (CCNC) today announced…

FinancialGlaxoSmithKlineHealthcareNorth AmericaPharmaceutical

176 to 200 of 414 results

COMPANY SPOTLIGHT

Menarini

Back to top